Immunovant, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Immunovant, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2023.
  • Immunovant, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$109M, a 86% decline year-over-year.
  • Immunovant, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$323M, a 26.5% decline year-over-year.
  • Immunovant, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$259M, a 22.9% decline from 2022.
  • Immunovant, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$211M, a 34.6% decline from 2021.
  • Immunovant, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$157M, a 45.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$259M -$48.4M -22.9% Apr 1, 2023 Mar 31, 2024 10-K 2024-05-29
2022 -$211M -$54.2M -34.6% Apr 1, 2022 Mar 31, 2023 10-K 2024-05-29
2021 -$157M -$49.3M -45.9% Apr 1, 2021 Mar 31, 2022 10-K 2023-05-22
2020 -$107M -$41M -61.8% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-08
2019 -$66.4M -$37.8M -132% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-01
2018 -$28.6M Apr 1, 2018 Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.